What You Should Know:
– WellRX, the parent company of preventative healthcare brands ReviveRX and Ways2Well, has acquired Bioreach, a cutting-edge bloodwork and genetics laboratory.
– The strategic acquisition brings advanced diagnostic capabilities in-house, allowing WellRX to streamline its preventative healthcare offerings and enhance patient care.
Expanding Access to Advanced Diagnostics
By integrating Bioreach’s laboratory services, WellRX can now offer a comprehensive suite of health tests across its ecosystem, including:
- Telehealth clinics: Provides seamless bloodwork integration for partner telehealth providers, enhancing patient care and convenience.
- Weight-loss programs: Offers data-driven insights to support personalized weight management plans.
- Testosterone therapies: Enables precise monitoring and optimization of hormone replacement therapies.
- Regenerative medicine services: Supports advanced diagnostics for regenerative medicine treatments.
Improving Efficiency and Speed
Bioreach’s state-of-the-art technology significantly improves testing efficiency, reducing turnaround times for bloodwork results from 5-7 business days to just one day. This faster turnaround benefits both patients and providers by enabling quicker diagnoses and treatment decisions.
“Bioreach is a transformative addition for WellRX and its subsidiaries,” said Brigham Buhler, Founder and CEO of WellRX. “By integrating Bioreach’s cutting-edge capabilities, we’re not only accelerating bloodwork turnaround times but also unlocking deeper insights into patient health through our pharmacy and telehealth partnerships. This acquisition empowers us to drive down costs, achieve seamless vertical integration, and deliver proactive, predictive care. Together, we are reshaping healthcare to focus on healthspan—and one day, even lifespan—offering unmatched innovation, efficiency, and value to patients, clinicians, and providers. The future of medicine starts here.”
